Moderna (MRNA) net income: −$2.8B
Moderna reported a net loss of −$2.8B for the year ended Dec 31, 2025.
From Moderna's filings with the SEC · Read the filing · MRNA stock page
Moderna net income by year
#3,738 of 3,748 US companies by net income · See the full ranking
| Year ended | Net income | Change |
|---|---|---|
| Dec 31, 2025 | −$2.8B | – |
| Dec 31, 2024 | −$3.6B | – |
| Dec 31, 2023 | −$4.7B | – |
| Dec 31, 2022 | $8.4B | -31% |
| Dec 31, 2021 | $12.2B | – |
Net income of similar companies
Companies in the same industry as Moderna, by SEC industry code, with the closest net income. Each name opens the same page for that company.
| Company | Net income, latest year | Year ended |
|---|---|---|
| Vaxcyte | −$767K | Dec 31, 2025 |
| Twist Bioscience | −$130M | Sep 30, 2026 |
| Kodiak Sciences | −$230M | Dec 31, 2025 |
| Scholar Rock Holding | −$378M | Dec 31, 2025 |
| Immunovant | −$506M | Mar 31, 2026 |
| Revolution Medicines | −$1.1B | Dec 31, 2025 |
| Moderna | −$2.8B | Dec 31, 2025 |
Questions and answers
What is Moderna's net income?
Moderna reported a net loss of −$2.8B for the year ended Dec 31, 2025.
Numbers as reported in Moderna's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology